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CIntroduction: Quality-of-life (QOL) assessments in frequently bleeding
atients with congenital hemophilia with inhibitors and their families
re confounded by preexisting arthropathy and family circumstances.
eriodic QOL assessments typically made on nonbleed days may not
rovide complete reflections of the burden on patients/families.
im: To evaluate the impact of bleeding episodes on patients/caregiv-
rs/families and the association between monthly QOL scores and pa-
ients’ average diary experiences. Methods: Frequently bleeding in-
hibitor patients (four bleeds in 3 months), or their caregivers,
provided daily assessment of EuroQol five-dimensional questionnaire
and EuroQol five-dimensional questionnaire visual analogue scale,
pain (11-point Likert scale), and family anxiety/stress/activity change
over 3 to 6 months. QOL scores were stratified by bleed/nonbleed days.
Results: Patient QOL assessments were recorded by 37 of the 39 en-
rolled patients/caregivers (3771 of 3777 eligible dairy days, 472 bleed/
3299 nonbleed days). Median (range) diary duration was 91 (66–180)
days, with 8.2% (0%–72.2%) bleed days. Mean health scores were signif- O
osto
al So
ttp://dx.doi.org/10.1016/j.jval.2012.05.005cantly worse on bleed days than on nonbleed days (P  0.0001 for all):
EuroQol five-dimensional questionnaire index, 0.66 versus 0.82; visual
analogue scale health, 69.7 versus 77.4; and pain score, 4.1 versus 1.8.
Bleed days also had higher (P  0.001) proportions of days with abnor-
alities in family anxiety/stress (42% vs. 30%) and family activity
hanges (34% vs. 21%). Conclusions: Assessing the impact of hemo-
hilia with inhibitors on patient/family QOL typically includes periodic
likely nonbleed day) evaluations reflecting baseline abnormalities.
aily assessment, however, indicated that frequent acute bleeds im-
air QOL beyond patient’s nonbleed day baseline. New approaches are
equired to assess the cumulative impact of frequent acute bleeds on
atients and their families.
eywords: bypassing agent, congenital hemophilia, DOSE, EQ-5D,
nhibitors, quality of life.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The World Health Organization in 1948 declared that health is a
state of complete physical, mental, and social well-being and not
merely the absence of disease.Quality of life (QOL) has been further
efined as the patient’s subjective perception of the impact of
isease and its treatments on his or her daily life; physical, psy-
hological, and social functioning; and well-being. In many
hronic and/or progressive disorders, the concepts of QOL and
urden of illness have been extended to include key caregivers
ffected by the often physical work of providing care, as well as
sychosocial impact.
Congenital hemophilia A and B are rare X-linked bleeding dis-
rders characterized by a deficiency in coagulation factor VIII
FVIII) or IX (FIX). Without consistent treatment such as routine
VIII or FIX replacement therapy to prevent bleeding, individuals
ith congenital hemophilia may experience recurrent bleeding,
* Address correspondence to: Ellis J. Neufeld, Children’s Hospital B
E-mail: ellis.neufeld@childrens.harvard.edu.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.resulting in chronic arthritic pain and acute bleeding pain [1].
Treatment of frequent bleeding episodes and disability from he-
mophilic synovitis and arthropathy because of hemarthroses
(joint bleeds) can result in decreased QOL for patients with con-
genital hemophilia and their caregivers. Even amongpatientswith
mild hemophilia A, joint damage because of prior hemarthroses
has been shown to have a negative effect on physical health–re-
lated QOL [2].
Because prevention and treatment of bleeding both are more
challenging for patients with congenital hemophilia who develop
alloantibodies (“inhibitors”) to replacement FVIII or FIX, these pa-
tients have been observed to have more joint abnormalities and
worse clinical/radiologic orthopedic scores than do age-matched
hemophilia patients without inhibitors [3,4]. For this reason, the
gold standard in treatment has been to try to eliminate the inhib-
itor by immune tolerance induction, typically using FVIII, to re-
store the potential to reinstate routine FVIII replacement. Results
of a recently discontinued international immune tolerance study,
n, 300 Longwood Avenue, Boston, MA 02115.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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917V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 1 6 – 9 2 5however, suggest that this might be effective only in approxi-
mately 54% of the young patientswith good prognostic risk factors
in the intent-to-treat population [5].
For the estimated 800 to 1000 patients in the United States with
congenital hemophilia complicated by inhibitors, acute bleeding
episodes can bemanaged with infusions of bypassing agents such
as recombinant activated factor VII (NovoSeven RT; Novo Nordisk
A/S, Bagsvaerd, Denmark) and the older plasma-derived activated
prothrombin complex concentrate (FEIBA NF; Baxter AG, Vienna,
Austria) [6,7]. In the developed world, patients with inhibitors
most often treat themselves in the home setting [8]. Early treat-
ment of bleeding episodes by using bypassing agents might min-
imize functional disability and preserve QOL for patients and care-
givers [9,10]. This suggests that the way patients and families
manage the treatment of bleeding episodes at home, and how this
affects daily life, deserves attention.
Quality-of-life assessments in patients with hemophilia com-
plicated by inhibitors are affected not only by bleeding episodes
but also by preexisting arthropathy and family circumstances
(e.g., two or more children with hemophilia). As a result, periodic
QOL assessments typically done on nonbleed days in prospective
clinical studies may not accurately reflect the burden on patients
and families. The Dosing Observational Study in Hemophilia
(DOSE) was a prospective, observational diary study in which the
primary objective was to evaluate the use of bypassing agents,
with a focus on the use of recombinant activated factor VII in the
home setting [11]. The secondary objective of the study was to
evaluate the day-to-day variability in QOL for inhibitor patients
(self- or caregiver-rated) and the impact of bleeding episodes on
QOL for patients and their families. Furthermore, the study aimed
to assess the correlation between QOL scores at monthly intervals
and patients’ average diary experiences to assess how reflective
periodic assessments might be. This report focuses on results
from QOL analyses from DOSE.
Materials and Methods
Study design
DOSEwas a phase IV diary study conducted between January 2008
and July 2009 at 20 sites in the United States that were federally
designated as hemophilia treatment centers (HTCs). Detailed
methodology is described elsewhere [11,12]. In brief, patients, or
their caregivers, completed diaries for at least 90 days, or until
patients experienced a minimum of four bleeding episodes. Bleed
and treatment data were collected without the involvement of the
HTC/physician to maintain the observational nature of the study
and prevent changes in the treatment of the patient’s disease due
to additional patient/caregiver communicationwith theHTC/phy-
sician. Daily QOL analyses were a preplanned secondary objective
of the study. The studywas conductedwith prior approval by local
institutional review boards and with written consent from the
subjects or their legal representatives.
Study population
Male patients with congenital hemophilia with inhibitors who ex-
perienced spontaneous bleeding were eligible for this observa-
tional study if they required treatment with bypassing agents for
at least four bleeding episodes of any type in the prior 3 months
and were prescribed recombinant activated factor VII as first-line
therapy for bleeding episodes (including breakthrough bleeding
with prophylaxis and immune tolerance therapy [ITT]). Patients
were categorized as on-demand treatment for bleeding (OD), sec-
ondary prophylaxis with bypassing agent (PPX), and/or ITT. Sub-
jects received standard care according to local practice, and treat-
ment decisions were made by the health care provider. Patientsand caregivers were encouraged to communicate in a standard
fashion with their treatment center during the study and to not
share any diary materials or treatment logs that would not other-
wise have been provided to their HTC.
Patient diaries
Patients or caregivers of minor patients kept daily diary records
capturing information on bleed and treatment status andwhether
it was a work or school day for the patient or the caregiver. Daily
QOL assessments by adult patients (or caregiver proxy assess-
ments of QOL for their sons aged 18 years) included the EuroQol
five-dimensional questionnaire (EQ-5D), a genericmeasure of QOL
that consists of five descriptive items (mobility, self-care, daily
activities, pain/discomfort, and anxiety/depression), each with
three levels of response (no, some problems, and extreme prob-
lems), and the standardized print presentation of a visual ana-
logue scale (EQ-5D-VAS, 0–100; higher scores indicate better
health) [13,14]. Permission of the EuroQOL Board [14] was obtained
or the novel use of EQ-5D as part of a descriptive analysis on a
aily basis as part of a diary, including caregiver assessment of
OL of their minor sons. In addition, adult patients (or caregivers
ssessing their minor sons) completed a standard 11-point Likert
ain score (pain, 0–10; higher scores indicating more pain) daily.
o be able to assess the impact of bleeding on families of adult
atients (spouses/partners, children) and children/adolescents
parents, caregivers, affected andunaffected siblings), novel rating
cales for family anxiety/stress (none, slight, moderate, a lot, or
xtreme) and family activity changes (none, some, moderate, ma-
or) were developed on the basis of patient/caregiver consulta-
ions. Additional information was recorded on 24-hour bleed
orms when a patient had a bleeding episode or reported ongoing
reatment after bleeding had already ended. This information in-
luded details of the bleeding episodes (i.e., cause, type, location,
nd symptoms), all bleed treatments on an hour-by-hour basis,
nterference of bleeding episodes with daily activities (for patient
nd caregivers), reasons for treatment decisions, bypassing agent
dministered, pain medications, and pain levels at the time of
ach dose.
Patients/caregivers kept primary diaries on paper, with an op-
ional Internet-based entry. Electronic diaries were submitted on-
ine in real time, whereas paper diaries were submitted monthly.
he standardized 20-cm EQ-5D VAS [13] was used on the paper
diaries and was transferred to electronic diaries as a numeric
value either by patients/caregivers or entered into the electronic
diary format by a third party (Outcome Sciences, Cambridge, MA).
AsWeb-based entry of EQ-5D-VAS health scores as an integer on a
0 to 100 scale had not been validated, a preplanned analysis to
correlate the reported VAS on the 20-cm scale with the number
reported was performed and is reported with the study method-
ology [11].
Patient and caregiver support
Throughout the study, an independent, dedicated patient-support
liaison group (Outcome Sciences) provided logistical support to
the patients and their caregivers. This individual contacted them
for matters concerning training, data clarification, overdue forms,
product box tops, and additional bleed forms and issued honoraria
for study participation as approved by local institutional review
boards. Electronic diary entry was monitored on a weekly basis,
and paper-only diaries collected monthly.
Statistical analysis
U.S. preference-weighted EQ-5D index scores were calculated on
the basis of themethod developed by Shaw et al. [15]. All bleeds on
all subjects were evaluated irrespective of treatment. Hierarchical
models to control for repeated measures within patients, stratifi-
918 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 1 6 – 9 2 5cation, and comparison with mean nonbleed scores were used to
evaluate instrument responsiveness to bleed and nonbleed days.
QOL data were processed on all patients who had at least one
bleeding episode and at least 7 days of QOL data past the end of the
bleed. Additional post hoc analysis of this data included assess-
ment of EQ-5D index, health, and pain scores across treatment
groups and pediatric and adult age groups.
Results
Patient demographics and bleeding episodes
Of 52 patients enrolled in the study, 39 completed the daily diaries
(23 adult diaries, 16 caregiver-reported diaries) and 37 completed
daily QOL assessments (19 adult patients, 18 caregivers on behalf
of patients). Baseline demographics and patient characteristics for
enrolled andQOLpopulations are shown inTable 1. Demographics
of patients who completed the QOL assessments did not differ
statistically from those of patients who did not complete the diary
or QOL assessments in any measured characteristics. Approxi-
mately half of all enrolled and QOL patients were older than 18
years. The majority of enrolled/QOL patients were white (71.2%/
73.0%) and non-Hispanic (65.4%/73.0%). Overall, about half had
central venous access devices, and this was more commonly seen
in children and adolescents. Slightly less than half had concomi-
tant chronic illnesses, the most common of those being hepatitis
C. Most patients were limited in recreational activities, work/
Table 1 – Demographic and patient characteristics.
Parameter Enrolled
population
(n  52)
QOL
population
(n  37)
Age (y)
Mean  SD 23.3  17.8 25.6  19.4
Median (range) 18.3  1.5–60.9 17.2  2.1–60.9
Age  18 21  51.9% 18  48.6%
Race, n (%)
White 37 (71.2) 27 (73.0)
Black/African American 9 (17.3) 8 (21.6)
Asian 2 (3.8) 1 (2.7)
Pacific Islander 2 (3.8) 0 (0.0)
Other 2 (3.8) 1 (2.7)
Ethnicity, n (%)
Hispanic or Latino 18 (34.6) 10 (27.0)
Not Hispanic or Latino 34 (65.4) 27 (73.0)
Other parameters, n (%)
Central venous line present 25 (48.1) 20 (54.1)
Concomitant chronic illness 22 (42.3) 17 (45.9)
Hepatitis C 17 (32.7) 12 (32.4)
Functional status, n (%)
Unrestricted 13 (25.0) 9 (24.3)
Full work/school, limited
recreational activities
9 (17.3) 7 (18.9)
Limited work/school and
recreational activities
20 (38.5) 13 (35.1)
Limited work/school, recreational,
and self-care activities
9 (17.3) 8 (21.6)
Requires assistance 1 (1.9) 0 (0.0)
Treatment type, n (%)
On-demand 37 (71.2) 22 (59.5)
Prophylaxis 12 (23.1) 12 (32.4)
Immune tolerance induction 5 (9.6) 5 (13.5)QOL, quality of life.school, and/or self-care activities; only one quarter reported “un-
restricted” functional status.
Themedian (range) number of historical bleeds over the prior 1
year was 13 (2–50), and themedian duration of study participation
was 91 days. Of the 39 patients who completed a diary, 38 reported
194 bleeding episodes and 1 had no bleeds during the diary com-
pletion period and was therefore not included in the bleeding and
QOL analyses. The allocation of patients, number and frequency of
bleeding episodes, and percentage of bleed days within the three
treatment groups andwithin the adult/pediatric diaries are shown
in Table 2.
Quality-of-life assessments
Daily QOL assessments (including EQ-5D, EQ-5D-VAS, and pain
score) were completed by 37 of the 39 patients who completed
diaries, for a total of 3771 of 3777 diary days (99.8%). Of completed
days, 472 (12.5%) were bleed days and 3299 were nonbleed days.
Approximately half of the bleed days recorded in this study were
not planned work or school days for patients (53%) or caregivers
(48%). Apart from formal QOL assessments (described later), the
specific impact of bleeding episodes on daily activities, productiv-
ity, and time spent with drug infusions is reported separately.
Across all diary days, the median (range) EQ-5D index, EQ-5D
VAS, and VAS pain scores were 0.81 (0.11 to 1.0), 83.0 (3.0–
100.0), and 1.0 (0.0–10.0), respectively. Mean health scores were
significantly worse on bleed days than on nonbleed days (P 
0.0001 for all) (Fig. 1). Mean health scores by patient were similar
to aggregate scores across all patient diary days combined
(Table 3).
For all categorical componentmeasures of QOL, the percentage
of diary days with any problems was significantly higher (P 
0.0001) for bleed days versus nonbleed days: EQ-5D dimensions—
mobility (66.7 vs. 51.3), self-care (49.8 vs. 27.8), usual activities (64.2
vs. 31.8), pain or discomfort (82.0 vs. 43.3), and anxiety or depres-
sion (32.2 vs. 18.5); EQ-5D index (scores 1 [i.e., full health]) (90.7
Table 2 – Treatment type and bleed frequency, bleeding
population.
OD ITT* PPX* All
Number of patients
Age  18 y 8† 4 10 19
Age  18 y 15 1 2 18
All 23 5 12 37
Number of bleeding events
Age  18 y 39 56 51 122
Age  18 y 62 2 8 72
All 101 58 59 194
Number of bleeding events
per patient
Age  18 y 4.9 14.0 5.1 6.4
Age  18 y 4.1 2.0 4.0 4.0
All 4.4 11.6 4.9 5.2
% of bleed days (median)
Age  18 y 8.9 26.3 8.2 8.9
Age  18 y 5.5 2.2 33.5 5.9
All 6.5 26.1 9.5 8.2
ITT, immune tolerance therapy; OD, on-demand treatment for
bleeding; PPX, secondary prophylaxis with bypassing agent; OQL,
quality of life.
* Two pediatric patients are in both ITT and PPX.
† One pediatric OD patient was in the bleeding population but did
not have caregiver-completed QOL.vs. 62.4%); EQ-5D VAS (scores 100 considered days with QOL
919V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 1 6 – 9 2 5problems) (94.3 vs. 81.8); and VAS pain (scores 0 [i.e., patients
reporting any pain]) (84.1 vs. 55.0) (Fig. 2A).
Similarly, across individual patient data, the percentage of pa-
tients with any problems with QOL in all categorical components
was high on all diary days, bleed days, and nonbleed days (Fig. 2B).
Fig. 1 – Mean health state for bleed versus nonbleed days—
QOL population. Calculated EQ-5D index, EQ-5D-VAS, and
pain scores across 472 bleed and 3299 nonbleed days. N
represents the number of bleed days. Error bars represent
SD. EQ-5D, EuroQol five-dimensional questionnaire; QOL,
quality of life; VAS, visual analogue scale.
Table 3 – QOL parameters across diary days and patients b
OD*
Age, n 22
Median (y) 38.9
Age  11, n (%) 4 (18.2)
Age 11–18, n (%) 3 (13.6)
Age  18, n (%) 15 (68.2)
Patient mean values, n 21
EQ-5D index, mean  SD
Bleed days 0.60  0.26††
Nonbleed days 0.79  0.19
EQ-5D-VAS (health), mean  SD
Bleed days 63.2  23.4
Nonbleed days 74.6  23.6
Pain score, mean  SD
Bleed days 4.4  2.3
Nonbleed days 2.2  2.3
Diary days, n (bleed/nonbleed) 2397 (210/2187)
EQ-5D index, mean  SD
Bleed days 0.64  0.27
Nonbleed days 0.78  0.21
EQ-5D-VAS (health), mean  SD
Bleed days 70.3  23.7
Nonbleed days 72.6  24.1
Pain score, mean  SD
Bleed days 4.5  2.5
Nonbleed days 2.3  2.4
EQ-5D index derived by Shaw et al. [15] method. Normative data from
index of 0.79 and VAS 84.19 [15]. Normative data in chronic condition
(66/0.725), stroke (67/0.694), emphysema (66/0.680), and rheumatoid a
EQ-5D, EuroQol five-dimensional questionnaire; ITT, immune toleran
phylaxis with bypassing agent; OQL, quality of life; VAS, visual analo
* One pediatric OD patient was in the bleeding population but did no
† Two pediatric patients are in both ITT and PPX.
†† P  0.01 vs. nonbleeding days.
§ P  0.05 vs. nonbleeding days.
 P  0.001 vs. nonbleeding days.Patients had significantly higher percentages of reported prob-
lems in several EQ-5D dimensions (mobility [P  0.0242], usual
activities [P 0.0060], and pain or discomfort [P 0.0462]) on bleed
days (94.4, 94.4, and 94.4, respectively) than on nonbleed days
(73.0, 67.6, and 75.7, respectively). In the other EQ-5D dimensions
(self-care and anxiety or depression), EQ-5D VAS, and VAS pain,
there was a trend toward lower QOL on bleed days than on non-
bleed days, but the differenceswere not significant because a large
proportion of patients reported a deviation fromperfect QOL (or no
pain) on both bleed and nonbleed days. The percentages of pa-
tients forwhom the diarywas taken in its entirety showed that “no
problems” were low, even on nonbleed days: EQ-5D dimensions—
mobility (27.0%), self-care (43.2%), usual activities (32.4%), pain or
discomfort (24.3%), anxiety or depression (43.2%); EQ-5D index
(13.5%); EQ-5D-VAS (2.7%); and VAS pain (27.0%) when analyzing
on a per-patient basis.
Bleeding also affected family anxiety/stress and resulted in
more changes to planned family activities (Fig. 3). Across all diary
days, bleed days had higher family anxiety and stress scores (42.4
vs. 29.7) and associated activity changes (34.5 vs. 21.2) than did
nonbleed days. For patient-level data, there was a trend toward
more abnormalities on bleed days than on nonbleed days. The
percentage of patients with no abnormalities was low, even on
nonbleed days, with 37.9% reporting at least some family anxiety/
stress and 43.2% reporting at least some activity changes.
Treatment regimens were not uniformly distributed by age,
with adults constituting the majority of OD patients and pediatric
atment group.
ITT† PPX† All
5 12 37
8.2 15.7 17.2
3 (60) 4 (33.3) 10 (27)
1 (20) 6 (50.0) 9 (24.3)
1 (20) 2 (16.7) 18 (48.6)
5 12 36
0.73  0.16 0.71  0.20†† 0.64  0.23
0.90  0.08 0.91  0.09 0.84  0.16
83.0  8.0§ 71.9  18.9 67.4  21.3§
92.3  4.0 84.9  17.0 79.2  21.1
2.8  1.8§ 3.5  2.0†† 4.0  2.2
0.6  0.7 1.1  1.6 1.7  2.1
450 (135/315) 1102 (171/931) 3771 (472/3299)
0.70  0.22 0.67  0.29 0.66  0.26
0.91  0.10 0.91  0.11 0.82  0.19
82.0  10.5 64.4  22.1 69.7  21.6
92.7  5.7 85.9  17.0 77.4  22.6
2.8  2.8 4.0  2.6 4.1  2.6
0.7  0.8 0.9  1.6 1.8  2.2
mple of individuals aged 18 to 99 y (mean 45 y) demonstrates mean
es: diabetes (mean age 60 y/mean index 0.758), myocardial infarction
tis (59/0.661) [16].
erapy; OD, on-demand treatment for bleeding; PPX, secondary pro-
cale.
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920 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 1 6 – 9 2 5patients constituting themajority of those on PPX and/or ITT. As a
result, the PPX and ITT populations were generally younger and
had differences noted in nonbleed day QOL (Table 3). Across all
diary days and mean scores by patient, scores were in most cases
still significantly lower on bleed days across all treatment regi-
mens. This discrepancy by age is further illustrated by a compar-
ison of pediatric QOL data entered by caregiverswith that of adults
as shown in Table 4. Across all diary days, bleed days were worse
thannonbleed days (P 0.0001) in both age groups across the three
ndices, and adults performed worse than children/adolescents
P  0.0001) with greater disability, worse health, higher pain
cross all dairy days, bleed days, and nonbleed days.
Hierarchical linear modeling of bleed and nonbleed days indi-
ated that all QOL assessments (EQ-5D dimensions, EQ-5D index,
Q-5D VAS, VAS pain, family anxiety, and family activity change)
Fig. 2 – Report of any problems in QOL metrics. Identification
other), EQ-5D index (1 vs. <1), EQ-5D VAS (100 vs. <100), and
days considered together (A) and within each patient (B). EQ
therefore, assessment for anything apart from “100” is not i
bleeding days. Anxiety and depression seem the least sensi
questionnaire; QOL, quality of life; VAS, visual analogue scaere significantly associated with bleed versus nonbleed states sP 0.001) after controlling for repeatedmeasures within patients
Table 5). The odds of reporting any problems on bleed days over
onbleed days were highest for EQ-5D dimensions, with unad-
usted odds ratios of 5.97 (pain or discomfort), 3.85 (usual activi-
ies), 2.57 (self-care), 2.10 (anxiety or depression), and 1.90 (mobil-
ty). This was followed by family activity change (1.97), family
nxiety and depression (1.74), and VAS pain (1.43). The QOL pa-
ameter most predictive of bleed state was the EQ-5D index, with
n unadjusted odds ratio of 0.05. (Note that this index is inversely
elated to health, with 1.0 representing perfect health.)
The EQ-5D-VAS andpain scores for two representative patients
re shown in Figure 4, illustrating the high degree of variability in
ome patients. Patient 1 is a 14 year old with, at most, very early
tage joint disease who functions with a nonbleed day VAS health
core of 100 and a pain score of 0. With bleeds, health and pain
ays with QOL affected: EQ-5D components (none vs.
score (0 vs. >0) in the QOL population across all diary
VAS is abnormal in almost all patients at some time;
mative. The other measures are variably sensitive to
and least prevalent. EQ-5D, EuroQol five-dimensionalof d
pain
-5D-
nfor
tive
le.cores are affected for about 1 to 3 days. Family anxiety and activ-
921V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 1 6 – 9 2 5ity changes (not shown)were also relatively limited to these bleed-
ing episodes. In contrast, patient 2 is a 41 year old with hemophilic
arthropathy whose baseline heath scores are in the 60 to 80 range
and whose pain scores are in the 5 to 7 range. Both scores show
some periodicity to the fluctuations, and most bleeding episodes
would be difficult to identify without being marked. Family anxi-
ety/stress and activity changes were associated with many noted
periodic increases in pain.
To better understand variability with bleed days, analysis was
done on eachQOL score or dimension on bleed days in reference to
Fig. 3 – Family anxiety, stress, and activity changes. Novel f
for this study across all bleed and nonbleed days. Caregiver
as a whole. Values were different on bleed versus nonbleed
Table 4 – QOL parameters across diary days and patients b
Age  18 y
Patient mean values, n 19*
EQ-5D index, mean  SD
Bleed days 0.76  0.111†
Nonbleed days 0.92  0.086
All days 0.89  0.096
EQ-5D-VAS (health), mean  SD
Bleed days 80.7  13.53†
Nonbleed days 92.3  10.16
All days 90.7  10.29
Pain score, mean  SD
Bleed days 3.0  1.77†
Nonbleed days 0.5  1.20
All days 0.9  1.27
Diary days, n (bleed/nonbleed) 1722 (219/1451)
EQ-5D index, mean  SD
Bleed days 0.75  0.190†
Nonbleed days 0.93  0.104
All days 0.90  0.138
EQ-5D-VAS (health), mean  SD
Bleed days 80.2  15.81†
Nonbleed days 92.5  10.93
All days 90.6  12.65
Pain score, mean  SD
Bleed days 3.1  2.59†
Nonbleed days 0.5  1.23
All days 0.9  1.80
EQ-5D index by Shaw et al. [15] method.
EQ-5D, EuroQol five-dimensional questionnaire; VAS, visual analogu
* n  19 for nonbleed days; n  18 for bleed days.
† P  0.0001 for bleed vs. nonbleed days.
†† P  0.005 for bleed vs nonbleed days.each patient’s mean nonbleed day value for that score or compo-
nent. For all patients and bleed types, 70.8% of bleed days had
more than one QOL score that was greater than 1 SD from the
patient’s mean nonbleed scores. VAS pain had the highest per-
centage of bleed days,with scores greater than 1 SD from themean
(30.9%), whereas the anxiety and depression dimension of the
EQ-5Dwas the least responsive (asmight be expected) at only 9.2%
(Fig. 5). Across bleed types, results were comparable for joint and
other bleed types; however, for muscle bleeds, scores for family
anxiety and stress most frequently exceeded 1 SD from the mean.
y anxiety and stress and activity change scales developed
adult patients completed assessments for their families
s (P < 0.0001).
e.
Age  18 y P for pediatric vs. adult
18
0.52  0.264†† 0.0011
0.75  0.180 0.0008
0.072  0.176 0.0001
54.1  19.45 0.0001
65.4  21.06 0.0001
64.3  20.99 0.0001
5.1 (2.04)†† 0.0022
3.0  2.07 0.0001
3.2  2.08 0.0001
2049 (201/1848)
0.54  0.293† 0.0001
0.74  0.206 0.0001
0.72  0.225 0.0001
53.6  20.23† 0.0001
65.5  22.34 0.0001
64.5  22.33 0.0001
5.3  2.07† 0.0001
2.9  0.223 0.0001
3.1  2.33 0.0001
e.amil
s and
dayy ag
e scal
922 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 1 6 – 9 2 5QOL scores exceeded 2 SD from the patient’s mean for 19.0% of
bleed days for all patients and all bleed types.
Relationships between patient mean QOL scores and those re-
ported on periodic index days (days 1, 30, 60, and 90 of the study)
were determined by Pearson correlations. For all measures, pa-
tient mean values positively correlated with scores on all peri-
odic index days (range 0.535–0.982) (Table 6). Correlations with
the patient’s mean experience showed moderate positive rela-
tionships on day 1 (range 0.535–0.840) and strong positive rela-
tionships on day 30 (range 0.758–0.982), day 60 (range 0.759–
0.950), and day 90 (range 0.735–0.974). The strongest correlation
with mean scores was observed for EQ-5D-VAS, which had val-
ues of 0.840, 0.982, 0.950, and 0.970 for days 1, 30, 60, and 90,
respectively.
Discussion
The current analyses of DOSE were designed to understand the
impact of bleeding episodes on the QOL of patients and caregivers
in a home treatment setting and to obtain additional information
about the burden of living with or caring for a child with hemo-
philia with inhibitors. The study was derived from a desire to
quantify the feedback obtained from patients and caregivers serv-
ing on a series of advisory boards about the nature of living with
hemophilia with inhibitors. Both groups were integral to devising
the study and providing feedback on the planned data capture.
The groups completed diaries on bleed and treatment status and
performed daily QOL assessments, which showed that all QOL
parameters were worse on bleed days and congruent with an in-
crease in family anxiety and stress. These results were also in
agreementwith our expectations because the inhibitor population
is distinctly different from the pediatric population of hemophilia
patients without inhibitors, which, during the past 5 to 10 years,
has grownupwith the gold standard of routine factor replacement
from birth (primary prophylaxis), providing an essentially normal,
Table 5 – Predictors of bleed/nonbleed states
(unadjusted odds ratio)—QOL population.
Unadjusted
odds ratio*
95% CI
Lower
limit
Upper
limit
EQ-5D components
Mobility 1.90 1.55 2.33
Self-care 2.57 2.11 3.13
Usual activities 3.85 3.14 4.71
Pain or discomfort 5.97 4.67 7.62
Anxiety or depression 2.10 1.70 2.59
EQ-5D index 0.05 0.03 0.07
EQ-5D-VAS 0.99 0.98 0.99
Pain score 1.43 1.37 1.48
Family anxiety 1.74 1.43 2.12
Family activity change 1.97 1.60 2.42
CI, confidence interval; EQ-5D, EuroQol five-dimensional question-
naire; HLM, hierarchical linear modeling; QOL, quality of life; VAS,
visual analogue scale.
* HLMmodel used for each variable as a predictor of bleed vs. non-
bleed state, with patient as a random effect in the model to ac-
count for patient variability. For EQ-5D components, family anx-
iety, and family activity, the odds ratio is calculated for some
problems vs. no problems (none). For the EQ-5D index, lower
values indicate worse health. P  0.001 for all indices and
components.nearly bleed-free childhood for those with severe factor deficien-cies. Secondary prophylaxis with bypassing agents serves to re-
duce the bleed frequency only by 45% to 60% [17–19], as evidenced
by our ability to recruit many secondary prophylaxis patients with
frequent breakthrough bleeding. Thus, arthropathy is likely to oc-
cur in all inhibitor patients at some point in time even with pro-
phylaxis.
Assessments of the impact of hemophilia with inhibitors on
the QOL of patients and their families typically include periodic
(likely nonbleed day) evaluations, reflecting baseline, day-to-
day QOL impairment caused by the progression of hemophilia.
Trials of bleeding treatments typically do not start in themiddle
of a bleeding episode, meaning that initial QOL samples are on a
nonbleed day and, thus, better than the patient’s average. Even
frequent bleeders are not bleeding most of the time, and, in this
study, only 8.9% of the overall days were associated with bleed-
ing or bleed treatment. Patients typically do not come in for
end-of-trial visits during a bleeding episode. Therefore, it is
likely that periodic or end-of-study QOL assessments are also
on nonbleed days. One implication of this is that periodic as-
sessments, as currently executed in trials, do not necessarily
Fig. 4 – Daily variability in VAS health score and pain
score. Graphical representations of VAS health scores and
pain scores in (A) patient 1, a young patient without
arthropathy, and (B) patient 2, an older patient with
arthropathy. Mean ± SD nonbleed versus bleed day EQ-5D-
VAS and pain scores for patient 1 were 100 ± 0.0 versus
90 ± 0.0 and 0.0 ± 0.0 versus 2.9 ± 3.0, and for patient 2
were 72.8 ± 5.6versus 58.1 ± 6.3 and 5.9 ± 0.8 versus 7.3 ±
1.3 for the older patient. These graphical representations
demonstrate patterns that would be missed in scheduled
periodic assessments. The extent of day-to-day variability
may be as important as the mean patient scores in
understanding patient perception of QOL. EQ-5D, EuroQol
five-dimensional questionnaire; QOL, quality of life; VAS,
visual analogue scale.
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923V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 1 6 – 9 2 5capture more than the impact of any treatment intervention on
the baseline QOL impairment and miss important QOL effects
that occur during the brief treatment periods on bleed days. For
those with arthropathy, baseline QOL is unlikely to be improved
by a change in bleed-specific treatment and can only remain the
same or get worse over the duration of a study.
To our knowledge, DOSE is the first diary study to look at
daily QOL assessments in a chronic disease state, including EQ-
5D. Daily assessments reveal additional information about the
QOL effect of bleeding episodes in the acute setting and about
QOL impairment associated with inhibitors in the long term.
Younger patients, as shown in Figure 4A, may exist in a rela-
tively normal health state between bleeding episodes. However,
they and their families are significantly affected by bleeding and
acute pain. Older patients with a history of ongoing bleeds into
their joints, as shown in Figure 4B, have a vicious cycle of bleed-
ing, acute synovitis with neovascularity, and rebleeding. The
result of the cycle is adults who have chronic arthropathy with
cartilage and bone changes and significant functional impair-
ment. For those patients, discrimination between QOL effects
attributable to bleed onset versus daily arthritic pain is reported
as difficult. These daily data demonstrating the variability in
particularly pain levels from day to day illustrate this patient
dilemma.
DOSE is also the first study to proactively look at the impact
of bleeding on patient and caregiver work/school by capturing
planned work/school days instead of just “lost” days. Surpris-
ingly, about half of the patient and caregiver bleed days were
not planned work/school days. As diary completion was distrib-
uted throughout the year, this suggests that for adult patients
with inhibitors, disability may be fairly common (i.e., no work/
school). In addition, for caregivers of these patients, at least one
parent may electively not work or not work full time to better
care for their child. In future studies, careful considerationmust
be given to documentation of patient disability, caregiver activ-
ities/work, and true lost work/school opportunities due to
bleeding episodes versus to the underlying condition.
The results of DOSE do not suggest that daily QOL measure-
ments could or should be the norm for assessing chronic dis-
eases such as hemophilia. The results, however, illustrate the
challenges in trying to quantify the burden of hemophilia and
the impact on the patient and the family by using purely period
assessments. Patients experienced no major difficulties com-
pleting QOL questionnaires on a daily basis. In fact, 37 of the 38
patients completing diaries and experiencing bleeding episodes
were willing to participate in QOL assessments for a small ad-
Fig. 5 – Proportion of bleed days that exceed 1 SD and 2 SD
from patients’ mean nonbleed scores. EQ-5D index, EQ-5D
VAS, pain score, family anxiety/stress, and activity change
scores. To the extent that each score is sensitive to the
effect of acute bleeding, one might expect the proportions
to exceed 1 or 2 SD from the patient’s nonbleed day mean.
EQ-5D, EuroQol five-dimensional questionnaire; VAS,
visual analogue scale.ditional honorarium. Different modes of data collection, paperas well electronic versions, were collected without a loss of pa-
tient reliability, and even EQ-5D-VAS measurements on paper
correlated with the patient’s reported numeric result on the
Web-based entry system in real time, demonstrating the reli-
ability of electronic data capture methods. Data collected on
days 1, 30, 60, and 90 correlated to a moderate degree with the
average patient experience over the interval.
Although the usefulness of daily QOL assessments in a pro-
spective clinical study is unclear, a common challenge faced in
hemophilia is to better characterize the effect of prophylaxis
treatments (routine FVIII/FIX replacement or with bypassing
agents for inhibitor patients) on QOL. The newer EQ-5D-5L scale
was not validated at the time DOSE was initiated, but it might
provide a similarly rapid but more discriminating assessment
score [20,21]. The newer EQ-5D-Y assessment scale for youths
(age  8 years) might have provided an alternative to caregiver
ssessment of their children/adolescents, but it was also still in
evelopment [22]. Hemophilia-specific tests may provide more
ensitive analyses that can supplement the use of standard
easures. There are only a few disease-specific QOL parame-
ers, however, and most have been recently developed [23–26].
he hemophilia-specific health-related QOL questionnaire was
riginally made available for use among children and adoles-
ents [23,25], and a separate version has been developed inde-
endently for adults [26]. The hemophilia-specific health-re-
ated QOL questionnaire for adults “discriminates” between
atients on the basis of severity of hemophilia and HIV status
nd has shown good correlation to results from the short form
6 health survey and the Health Assessment Questionnaire –
unctional Disability Index [26].
Future clinical trials may help to provide a better under-
tanding of the significance of using these tests; however, based
n the data shown here, the baseline QOL assessments on the
onbleed start day of a short-term study (3–12 months) could
asily reflect simply patient age and the presence of arthropa-
hy (fixed joint damage) associated with prior joint bleeds. Even
f the number of bleeds or the severity of bleeds was reduced,
he data from DOSE suggest that it would be unlikely that a
cheduled assessment at study completion would show im-
rovement, and, given the possibility of bleeding on that day
see Fig. 4B), might show worsening despite an obvious QOL
mprovement over the interval. In the short term of a typical
tudy (3–12 months), it is unlikely that baseline QOL on the
onbleed day of study start would improve by study completion
ecause the study is not directed toward reducing inflamma-
Table 6 – Correlation of patient mean daily scores with
patient days 1, 30, 60, and 90 scores.
Day 1 Day 30 Day 60 Day 90
EQ-5D components
Mobility 0.535 0.914 0.881 0.974
Self-care 0.610 0.917 0.827 0.888
Usual activities 0.714 0.758 0.895 0.879
Pain/discomfort 0.615 0.806 0.893 0.929
Anxiety/depression 0.636 0.884 0.759 0.835
EQ-5D index 0.504 0.928 0.867 0.930
EQ-5D-VAS (health) 0.840 0.982 0.950 0.970
VAS (pain) 0.716 0.906 0.923 0.921
Family anxiety 0.638 0.907 0.877 0.735
Family activity change 0.774 0.921 0.900 0.785
EQ-5D index by Shaw et al. [15] method.
EQ-5D, EuroQol five-dimensional questionnaire; VAS, visual ana-
logue scale.
924 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 1 6 – 9 2 5tion, as might be the case in a trial of immune modulation for
arthritis.
There are limitations of this study and these data. Although
the sample size for DOSE was low (52 patients), which may limit
statistical power, this sample constitutes nearly 7% of all US
patients with high-titer inhibitors and had a 75% completion
rate. It is well known that patients/caregivers sometimes com-
plete bleed logs en route to a clinic visit. Electronic capture in
real time for 24 of the 39 diaries with weekly monitoring, how-
ever, gives confidence that these reports were in real time, and
in addition, review of the detailed monthly paper submissions
reveals comments inserted in the margins, reflecting that the
patients/caregivers likely completed (at least many paper dia-
ries) in real time. Most of DOSE sites were large HTCs, might
disproportionately treat patients with higher disease severity.
Furthermore, patients in this study underwent a mix of treat-
ment regimens, fromOD through secondary PPX with bypassing
agents to reduce bleed frequency. The mix of treatments is un-
equally distributed by age (adults were more likely OD), and the
choice of treatment is likely affected by the severity or progres-
sion of arthropathy. Small numbers of particularly young chil-
dren within the ITT and PPX groups coupled with potential over-
lap between those groups further limits analysis. Irrespective of
treatment regimen, patients needed to meet an entry criterion
of four or more bleeds in the previous 3 months, which, for
patients taking prophylaxis and showing this many break-
through bleeds, implies that their preprophylaxis bleed fre-
quency may have been more than two to three bleeds per
month. This also limits the generalizability of the QOL esti-
mates in this study to patients who do not experience bleeds as
frequently. In addition, while some QOL measures used were
presented in their standard format (e.g., EQ-5D-3L with VAS),
they have not been validated specifically for daily use or for use
by caregivers in proxy rating of pediatric patients. In terms of
proxy assessments by caregivers, the relatively nonoverlapping
categories for mobility, self-care, and daily activities lend them-
selves more easily to proxy assessment than pain and anxiety/
depression, particularly when it comes to infants and small
children who would be too young even for the new EQ-5D-Y tool
[22]. The family anxiety/stress and activity change scales were
unique to this study and were meant to be exploratory. There
are also statistical considerations in multiple sampling of the
same patient at frequent intervals.
Conclusions
Apart from the already reported, very interesting observations
about home treatment and decisionmaking by the patient/care-
giver [11,12], DOSE demonstrated three key findings related to
QOL. First, there are methodological limitations to the tradi-
tional periodic assessments, particularly given that baseline
values are universally nonbleed days (best possible QOL). Sec-
ond, patients with chronic arthropathy have more impairment
in baseline QOL and have variability in nonbleed days that
would likely be common with any degenerative joint disease or
chronic disease characterized by an episodic course. Last, as
expected, bleeding days are worse and are particularly marked
by reduced patient and family activity with more pain. Thank-
fully, bleeding days represent a minority of the patient’s life,
and there are other factors that more significantly affect overall
score and day-to-day variability in the nonbleeding state. New
approaches are required to adapt validated health-related QOL
assessment tools for more frequent assessments that can help
quantify the cumulative impact of acute bleeding associatedwith different treatment paradigms on the patient, as well as
assess the QOL impact and burden on the caregiver and family.
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